One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus
doi : 10.1136/gutjnl-2024-332679
December 2024 - Volume 73 - 12
Cholesterol’s new tricks propel MASH-HCC: impact in immunotherapy
Is mailed outreach and patient navigation a perfect solution to improve HCC screening?
Animal experiments of a new through-the-scope full-thickness endoscopic suturing device
Puerarin alleviates atherosclerosis via the inhibition of Prevotella copri and its trimethylamine production
Clinical outcomes of potential coeliac disease: a systematic review and meta-analysis
Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells
MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer
TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism
Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease
Stomach microbiota in gastric cancer development and clinical implications
Recurrent intestinal ulcers and perforations complicated with pigmentation
Re-evaluating early-onset OSCC in Africa: findings of minimal cumulative incidence
Short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study
Author reply to: Exploring the impact of short-acting GLP-1 receptor agonists on GERD risk
Microscopic pathology assessment of colorectal polyp size is less accurate than intracolonoscopic assessment
Predicting treatment response in ASUC: do we measure systemic severity, organ response or both?
Response to: short-chain fatty acids in patients with severe acute pancreatitis: friend or foe?
Cholecystectomy following EUS-guided gallbladder drainage in patients with acute cholecystitis at high surgical risk: friend or foe?
Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease
Strengths and limitations of AlphaMissense in CPA1 missense variant classification
Correction: The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines
